The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment

A panelist discusses how targeted gene therapy has revolutionized BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) treatment through agents like nadofaragene firadenovec, which shows promising complete response rates at 3 months, though long-term follow-up remains crucial for assessing durability of response and comparing real-world outcomes with clinical trial data.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Overview of BCG-Unresponsive NMIBC

EP: 2.Challenges of BCG-Unresponsive NMIBC

EP: 3.Standard Treatment Options for BCG-Unresponsive NMIBC

EP: 4.Unresponsive NMIBC: Gene Therapies

EP: 5.Gene Therapy Considerations for BCG-Unresponsive NMIBC

EP: 6.Gene Therapy Data for BCG-Unresponsive NMIBC

EP: 7.BCG-Unresponsive NMIBC: Insights for Newer Treatment Modalities

EP: 8.Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs

EP: 9.Current Treatment Options for BCG-Unresponsive NMIBC

EP: 10.The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC

EP: 11.Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

EP: 12.Discussing Treatment Options for BCG-Unresponsive NMIBC

EP: 13.Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC

EP: 14.Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC

EP: 15.Enhancing Access to BCG-Unresponsive NMIBC Treatments

EP: 16.Navigating BCG-Unresponsive NMIBC and Emerging Therapies

Now Viewing

EP: 17.The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment

EP: 18.BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

EP: 19.Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC

EP: 20.Adoption of New Treatments for BCG-Unresponsive NMIBC

EP: 21.Future Directions of BCG-Unresponsive NMIBC Management

• How has the introduction of targeted gene therapy changed the way you approach the management of BCG-unresponsive NMIBC?
• What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, and how does nadofaragene firadenovec fit into this landscape overall?
• Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
• How do these clinical trial outcomes compare with what you see in your clinical practice when treating patients with newer therapies?
• Discuss the importance of long-term follow-up for patients receiving these newer treatments.
• What is your experience in terms of durability of response?

Related Videos

Future Directions of BCG-Unresponsive NMIBC Management

Adoption of New Treatments for BCG-Unresponsive NMIBC

Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC

BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

Navigating BCG-Unresponsive NMIBC and Emerging Therapies

Enhancing Access to BCG-Unresponsive NMIBC Treatments

Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC

Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC

Discussing Treatment Options for BCG-Unresponsive NMIBC

Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up